We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
Sandbox Reserved 1735
From Proteopedia
(Difference between revisions)
| Line 19: | Line 19: | ||
==HIV-2 Protease in Humans== | ==HIV-2 Protease in Humans== | ||
| - | ==The role of CD4+ T | + | ==The role of CD4+ T cell== |
| + | |||
| + | The CD4+ T cell is a lymphocyte, also known as a white blood cell, that fights infection. HIV attacks the CD+ T cell by binding and replicating through the CD4 + T cell. HIV kills CD4+ T cells which results in low immunity. An HIV-infected person with very low CD4+ T cells can develop AIDS. AIDS stands for acquired immune deficiency syndrome. HIV can remain latent in the body through memory T cells. Because HIV can remain latent in the body, patients with HIV can experience periods without symptoms. Patients who do die from HIV/AIDS die from secondary infections because of their compromised immunity from low CD4+ T cells. Most infections that kill HIV/AID patients are opportunistic infections. Research suggests that HIV-1 is better at killing CD4+ T cells than HIV-2. This is one reason why HIV-1 is more likely to progress into AIDS than HIV-2 (Vijayan et. al, 2017). | ||
==Protease Inhibitors for HIV-1 Treatment== | ==Protease Inhibitors for HIV-1 Treatment== | ||
Revision as of 20:29, 14 November 2022
| This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749. |
To get started:
More help: Help:Editing |
HIV-1 Protease
| |||||||||||
